Use of the Archimedes biodegradable stent at ERCP
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S344-S345
DOI: 10.1055/s-0044-1783541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von S. Dwarampudi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
The Archimedes biodegradable stents (ABS) are licensed for use in ERCP. Its unique design allows for drainage through and around the stent. The aim of this study was to evaluate the clinical use in both biliary and pancreatic indications in paediatric and adult patients.
Methods
This was a retrospective study of an unselected population of 132 patients who received biodegradable Archimedes stent during an ERCP between November 2018 and March 2023. Cases were searched and checked against electronic patient records. Data collected included baseline characteristics, indications for ERCP, Archimedes stent placement and size and length of the stents used. All discharge summaries and further admissions post ERCP were checked for complications.
Results
138 ABS were inserted into 132 patients of which 6 patients received both pancreatic and biliary stents during their procedure. 20 patients were paediatrics (mean age 11.8 – IQR 3.2-17) and 112 patients were adult (mean age 53.5 – IQR 19-93).96 pancreatic ABS were placed (n=89 fast degradation and n=7 slow degradation stents). Fast degradation stents were placed to mitigate against pancreatitis, dilated pancreatic duct (PD) or strictured PD due to pancreatitis stones. Slow pancreatic degradation stents were placed due to sphincter of Oddi dysfunction or chronic pancreatitis. The commonest fast pancreatic stent used was 6Fr 6cm. 42 biliary Archimedes stents were placed (n=2 fast degradation and n=40 slow degradation stents). Slow degradation stents were placed for bile leak or cholelithiasis. Fast degradation stents were inserted for benign stricture or stone fragmentation removal. The commonest slow biliary stent used was 8Fr 8cm. 134/138 (97.1%) ABS were placed successfully. 4/138 (2.9%) were placed unsuccessfully due to stent placement difficulties or procedural issues. There were no sphincterotomy bleeds or perforations reported and there were no reported cases of any complications relating to the Archimedes stent post-insertion. Overall, 79/132 patients (59.8%) required a pancreatic stent to mitigate against pancreatitis as the PD was initially cannulated or contrast was injected – only 4/132 (3.0%) developed pancreatitis post-ERCP.
Conclusions
The ABS is safe and highly efficacious in the use of both pancreatic and biliary indications at ERCP. Degradation rates were as predicted. Further indications for the use of the ABS appear to be evolving in clinical practice. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Dwarampudi, S., Farsi, U. A., Devlin, J., Barnabas, A., Harrison, P., Reffitt, D., & Joshi, D. (2024). Use of the Archimedes biodegradable stent at ERCP. Endoscopy, 56(S 02 S 02), S344-S345. https://doi.org/10.1055/s-0044-1783541
Vancouver
Dwarampudi S, Farsi UA, Devlin J, Barnabas A, Harrison P, Reffitt D, et al. Use of the Archimedes biodegradable stent at ERCP. Endoscopy. 2024;56(S 02 S 02):S344-S345. doi:10.1055/s-0044-1783541
BibTeX
@article{Dwarampudi2024,
author = {Dwarampudi, S. and Farsi, U. Al and Devlin, J. and Barnabas, A. and Harrison, P. and Reffitt, D. and Joshi, D.},
title = {Use of the Archimedes biodegradable stent at ERCP},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S344--S345},
doi = {10.1055/s-0044-1783541}
}
EUVIMED